Dose Escalation Study of IL-7 and Bi-therapy in HCV Patients Resistant After 12 Weeks of Bi-therapy (ECLIPSE 1)

Status:
Completed

Trial end date:
2012-03-01

Target enrollment:

Participant gender:

This study will evaluate the safety of a new experimental drug, IL-7, in people with HCV infection resistant after 12 weeks of bi-therapy.

Phase 1/Phase 2

Cytheris SA

Interferons
Ribavirin